Cencora report flags payer restrictions as key barrier to health system pharmacy growth

By Public Technologies
  • Cencora published a Fall 2026 Pharmacy Outlook survey of 110+ health-system pharmacy leaders on growth priorities amid payer restrictions.
  • More than half described strategy as growth-oriented, led by pharmacy financial performance and revenue capture at 87%.
  • Biosimilar adoption and formulary optimization followed at 85%; specialty pharmacy expansion and infusion growth each registered 79%.
  • Patient access remained constrained: 69% of specialty prescriptions were still dispensed externally, driven by payer network limits at 77%.
  • Cell and gene therapy readiness lagged: 100% of adopters involved pharmacy, yet only 5% reported pharmacy leads program management.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cencora Inc. published the original content used to generate this news brief on October 14, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.